arrow
M

Michael C. Burger

Senckenberg Institute of Neurooncology
H指数:19
被引数:2,275

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Age-associated epigenomic heterogeneity in papillary tumors of the pineal region: a multicenter YoungNOA investigation

松果体区乳头状肿瘤中的年龄相关表观基因组异质性:一项多中心YoungNOA研究

2026-08-280
OA
Local CAR-NK cell therapy in combination with systemic checkpoint inhibition induces anti-tumor responses even in distant tumor locations in an immunocompetent glioblastoma mouse model

局部CAR-NK细胞疗法与全身性检查点抑制相结合,即使在免疫健全的胶质母细胞瘤小鼠模型中的远端肿瘤部位也能诱导抗肿瘤反应。

2025-11-010
OAAI
THE MOLECULAR LANDSCAPE AND ITS PROGNOSTIC IMPLICATIONS IN ADULT PAPILLARY TUMORS OF THE PINEAL REGION - A MULTICENTER YOUNGNOA INVESTIGATION

松果体区成人乳头状肿瘤的分子景观及其预后意义——一项多中心YoungNoa研究

2025-11-010
PRE
EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

EO2401多肽免疫疗法联合纳武利尤单抗及/或贝伐珠单抗治疗首次复发的胶质母细胞瘤:EOGBM1-18 / ROSALIE(NCT04116658)研究中的治疗策略优化(I/II期研究)

2025-11-010
OAAI
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial
2025-09-050
OAAI
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort

伦伐替尼联合帕博利珠单抗用于先前接受过治疗的特定实体瘤患者:来自LEAP-005研究复发胶质母细胞瘤队列的2期研究结果

Cancer
IF5.1
2025-08-130
OAAI
Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

健康相关生活质量及认知功能在寡形胶质细胞瘤幸存者中的表现:一项国际横断面调查

2025-08-011
OAAI
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma

CAR-NK细胞疗法与免疫检查点抑制相结合在胶质母细胞瘤中诱导了NKT细胞反应

2025-03-180
OA
HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
2024-11-110
PRE
MODULATION OF THE INTRATUMORAL IMMUNE MICROENVIRONMENT BY LOCAL THERAPY WITH NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中,通过用HER2-TARGETED嵌合抗原受体工程化的自然杀伤细胞局部治疗与全身ANTI-PD-1检查点抑制相结合来调节肿瘤内免疫微环境

2024-11-110
PRE
FINAL RESULTS FROM N2M2/NOA-20

N2M2/NOA-20的最终结果

2024-11-110
PRE
FIRST IN HUMAN STUDY OF THE MRNA-BASED CANCER VACCINE CVGBM IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (GBM): FIRST RESULTS FROM THE DOSE ESCALATION PHASE
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
2024-10-170
PRE
A REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA

在复发性胶质母细胞瘤患者中重复颅内注射单独使用HER2-TARGETED嵌合抗原受体并结合全身ANTI-PD-1检查点抑制的自然杀伤细胞

2024-10-170
PRE